Efficacy of pembrolizumab and biomarker analysis in patients with WGS-based intermediate to high tumor mutational load: results from the Drug Rediscovery Protocol.
Birgit S GeurtsLaurien J ZeverijnLindsay V M LeekJ Maxime van Berge HenegouwenLouisa R HoesHanneke van der WijngaartVincent van den NoortJoris van de HaarAnnemiek van Ommen-NijhofMarleen KokPaul RoepmanAnne M L JansenWendy W J de LengMaja J A de JongeAnn HoebenCarla M L van HerpenHans M WestgeestLodewyk F A WesselsHenk M W VerheulAndré B P van KuilenburgEmile E VoestPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
While in cohort A pembrolizumab lacked activity, cohort B and cohort C met the study's primary endpoint. Further research is warranted to refine selection of patients with tumors harboring lower TMLs and may benefit from a focus on innate immunity.